GlassScriptPhysician profile
Jeanette Leader
NPI 1962498758
$5,094.86
in general payments reported to CMS, 2019-2025
37 companies · $792 in 2025
The $792 reported for 2025 was more than what 88% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $551 · 2020: $482 · 2021: $1,058 · 2022: $909 · 2023: $672 · 2024: $631 · 2025: $792.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,896 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,895.98 |
| Education | $198.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,438.72 | 2019-2025 | |
| Astellas Pharma US INC | $528.48 | 2022-2025 | Veozah, Myrbetriq |
| Mayne Pharma Commercial LLC | $502.18 | 2021-2025 | |
| Pfizer INC. | $245.66 | 2021-2024 | |
| Myovant Sciences INC. | $209.69 | 2021-2022 | |
| Evofem Biosciences, INC. | $194.25 | 2021-2025 | Phexxi, Solosec, Phexx |
| Agile Therapeutics, INC. | $176.88 | 2021-2023 | Twirla |
| Sumitomo Pharma America, INC. | $173.91 | 2023-2025 | Myfembree, Gemtesa |
| Therapeuticsmd, INC. | $160.74 | 2019-2022 | |
| Daiichi Sankyo INC. | $157.17 | 2019-2022 | |
| Amgen INC. | $134.30 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $117.52 | 2019-2025 | |
| Baxter Healthcare | $106.39 | 2025 | Tisseel, Floseal |
| Organon LLC | $104.58 | 2021-2025 | Nexplanon, Jada System |
| Hologic Sales and Service, LLC | $92.99 | 2019-2025 | Aptima, Acessa Provu System |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scynexis, INC. | $88.32 | 2022 | |
| Biogen, INC. | $84.34 | 2024-2025 | Zurzuvae |
| Optumhealth Care Solutions, LLC | $74.09 | 2025 | Vivify Health Care Team Portal 001, Eitan Medical |
| Coopersurgical, INC. | $58.43 | 2021-2022 | |
| Millicent US INC | $54.26 | 2019-2025 | Femlyv, Intrarosa |
| Exact Sciences Corporation | $35.29 | 2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $33.40 | 2020-2025 | Gardasil 9 |
| Avion Pharmaceuticals | $33.32 | 2019-2023 | Balcoltra |
| Exeltis, USA INC. | $33.11 | 2021-2024 | Slynd |
| Convatec INC. | $27.34 | 2021 | |
| Innovation Technologies INC | $25.73 | 2025 | Irrisept |
| Meditrina | $25.72 | 2023 | |
| Allergan, INC. | $24.36 | 2019 | |
| Medtronic, INC. | $24.12 | 2024 | Interstim |
| Hologic INC | $20.18 | 2021 | |
| Vertical Pharmaceuticals, LLC | $19.35 | 2020 | |
| Lupin INC. | $18.33 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.91 | 2021 | |
| Davol INC. | $15.24 | 2020 | |
| Amag Pharmaceuticals, INC. | $14.79 | 2020 | |
| Medicem INC. | $13.75 | 2020 | |
| Virtus Pharmaceuticals LLC | $12.02 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeanette Leader listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.